Hovione invests $170 million in new capacity and capabilities
PR 92988
MILAN, November 11, 2021, /PRNewswire=KYODO JBN/--
Hovione, the global leader in spray drying and particle engineering, today
announced that it is expanding its industrial facilities around the world to
support its ambitious growth objectives. The company has been on an expansion
track since 2016 in Portugal, Ireland and New Jersey with the aim of continuing
to increase its capacity and capabilities to address customer needs.
The announcement of a $170 million investment in Hovione units in Portugal,
Ireland, and New Jersey, leading to a global capacity increase of approximately
25%, was made at CPhI Wordwide, in Milan, by Guy Villax, CEO, and Jean-Luc
Herbeaux, COO.
These investments will be used to support growth in the company´s pharma custom
development and manufacturing service business, fueled by strongly growing
demand for Hovione´s integrated and differentiated services in drug substance
manufacturing, particle engineering and most recently drug product
manufacturing. The expansion will go hand-in-hand with a build-up of Hovione´s
global team with the creation of more than 300 new jobs globally. This strategy
will allow the company to continue to address difficult-to-meet client needs
while reinforcing its commitment to the Hovione values and standard of quality.
In the USA, Hovione will add a 2900m2 building next to its current facility in
East Windsor, New Jersey, laying the foundations for a state-of-the-art Hovione
Campus. The upcoming cycle of investment will bring additional commercial spray
drying capacity online by 2023. Further investments will follow with the aim to
solidify the company´s integrated offer: API - Particle - Drug Product in the
region. This expansion will allow Hovione to accompany existing and new
customers favoring US-based manufacturing through their development cycles all
the way to commercial.
The capacity and capabilities of Hovione´s Cork site in the Republic of Ireland
will also be upgraded to enable the production of Highly Potent Active
Pharmaceutical Ingredients (HPAPI) and to facilitate onboarding of Drug
Substance Manufacturing projects of all sizes. The investment will create an
ecosystem in which large customer projects with unique technologies can find a
home by connecting to the existing infrastructure and equipment. The site will
also receive a new commercial size spray dryer to support the growing demand
for particle engineering services.
In Portugal, Hovione is ready to start operations of its most recent facility
with an increase in chemical synthesis capacity for High Potency Active
Pharmaceutical Ingredients (HPAPI). The building is also prepared to receive a
new commercial spray dryer to respond to the future needs of the global drug
market.
"Hovione is in it for life and what better way to manifest this than through
expansion of our global capacity and capabilities. Our sustainable organic
growth strategy will allow us to keep true to those values that have been
guiding us for more than 60 years", says Guy Villax, Chief Executive Officer.
"These investments reinforce our integrated specialized offer globally,
providing our clients with a line of sight for their projects. Focus is placed
on facilitating and speeding up the drug development cycle and launch, by
providing API manufacturing, Particle Engineering and Tableting services in
each site. Our strategy continues to be to grow organically via investments in
our existing sites, which are designed for purpose. This reduces the
complexity associated with the growth journey and allows us to focus our
management attention on what counts most, i.e. guaranteeing that our clients go
to market with quality, safe and effective medicines for their patients" says
Jean-Luc Herbeaux, Hovione's Chief Operation Officer.
About Hovione
Hovione(https://www.hovione.com/) is an international company with over 60
years of experience as a Contract Development and Manufacturing Organization
(CDMO) and is currently a fully integrated supplier offering services for drug
substance, drug product intermediate and drug product. With four FDA inspected
sites(https://www.hovione.com/hovione-worldwide) in the USA, China, Ireland and
Portugal and development laboratories in Lisbon, Portugal and New Jersey, USA,
the company provides branded pharmaceutical customers services for the
development and compliant
manufacture(https://www.hovione.com/products-and-services/contract-manufacturing
-services/particle-engineering) of innovative drugs including highly potent
compounds. For generic pharmaceutical customers the company offers niche API
products. Hovione also provides proprietary product development and licensing
opportunities for drug
products(https://www.hovione.com/products-and-services/contract-manufacturing-se
rvices/drug-product/drug-product-development. In the inhalation area, Hovione
is the only independent company offering a complete range of services.
Isabel Pina, ipina@hovione.com, Tel.: 0035121 982 9362
Logo - https://mma.prnewswire.com/media/1686008/Logo_Hovione_Logo.jpg
SOURCE: Hovione
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。